Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours

NCT02076620 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT02076620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Lead sponsor
Philogen S.p.A.
Phase
Phase 1
Overall status
Completed
Start date
January 16, 2013
Completion date
January 25, 2018
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors amenable to anthracycline therapy, sarcoma, breast cancer, lung carcinomas, and gynecological cancer amenable to anthracycline therapy